GlassScriptPhysician profile
Christopher H Chang
NPI 1417981796
$50,784.07
in general payments reported to CMS, 2019-2025
32 companies · $6,666 in 2025
The $6,666 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,592 · 2021: $3,739 · 2022: $5,290 · 2023: $2,086 · 2024: $15K · 2025: $6,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,285 · Consulting Fee: $2,900 · Travel and Lodging: $1,675 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Food and Beverage | $8,285.40 |
| Consulting Fee | $2,900.00 |
| Travel and Lodging | $1,675.47 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26,555.96 | 2019-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $12,372.66 | 2023-2025 | Vowst, Zenpep |
| Mirum Pharmaceuticals, INC. | $3,512.77 | 2025 | |
| Abbvie INC. | $2,602.38 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Enterra Medical, INC. | $1,584.48 | 2024-2025 | |
| Ardelyx, INC. | $808.04 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $475.66 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $415.89 | 2023-2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $247.94 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $203.67 | 2024 | Iqirvo |
| Erbe USA INC | $166.32 | 2022-2023 | Erbe Vio3 Apc3 Erbejet |
| Regeneron Healthcare Solutions, INC. | $164.62 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $159.00 | 2025 | Rezdiffra |
| Exelixis INC. | $150.88 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $139.59 | 2024 | Tremfya, Stelara |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $138.44 | 2022 | |
| Boston Scientific Corporation | $134.58 | 2020-2023 | |
| Regeneron Pharmaceuticals, INC. | $132.82 | 2025 | Dupixent |
| Qol Medical, LLC | $124.25 | 2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $119.73 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $111.84 | 2023 | Givlaari |
| Celgene Corporation | $103.19 | 2023-2024 | Zeposia |
| Covidien LP | $100.29 | 2020 | |
| Olympus America INC. | $63.19 | 2020-2025 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Intercept Pharmaceuticals, INC. | $50.31 | 2019-2025 | Ocaliva |
| Ucb, INC. | $34.20 | 2019 | |
| Array Biopharma INC | $29.43 | 2025 | Braftovi, Tukysa |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Shire North American Group INC | $19.01 | 2019 | |
| Cook Medical LLC | $17.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.